“…Due to a growing interest for the combination of radiotherapy with immunotherapy, and the impact of one on another, EDIC models were calculated in several studies. Based on these models which are now well established for thoracic and upper abdominal localizations [18] , [40] , [41] , [42] , [43] , [44] , we could propose some explanations to our results. A trial including patients treated for stage III NSCLC reported a median EDIC of 6.1 Gy, which is higher than the EDICs we calculated [43] .…”